Sturge-Weber syndrome (SWS), also called encephalotrigeminal angiomatosis, is a neurocutaneous disorder with angiomas that involve the leptomeninges (leptomeningeal angiomas [LAs]) and the skin of the face, typically in the ophthalmic (V1) and maxillary (V2) distributions of the trigeminal nerve. The hallmark of SWS is a facial cutaneous venous dilation, also referred to as a nevus flammeus or port-wine stain (PWS).
Signs and symptoms
SWS is generally diagnosed clinically, based on the typical cutaneous, central nervous system (CNS), and ocular abnormalities associated with it. Neurologic signs include the following:
Developmental delay/mental retardation
Attention deficit-hyperactivity disorder
Factors suggesting a progressive course of cortical damage in SWS include the following:
Initial focal seizures progressing to frequent, secondarily generalized seizures
Increasing seizure frequency and duration despite the use of antiepileptic drugs (AEDs)
Increasing duration of a transient postictal deficit
Increase in focal or diffuse atrophy - Determined by serial neuroimaging
Progressive increase in calcifications
Development of hemiparesis
Deterioration in cognitive functioning
Physical signs of SWS are as follows:
Ocular involvement in SWS may include the following signs:
Hemangiomalike, superficial changes (which on histology demonstrate only venous dilation) in the eyelid
Tomato-catsup color of the fundus (ipsilateral to the nevus flammeus) with glaucoma
Conjunctival and episcleral hemangiomas
Diffuse choroidal hemangiomas
Heterochromia of the irides
Tortuous retinal vessels with occasional arteriovenous communications
Ocular signs that may indicate the presence of infantile glaucoma include the following:
Corneal diameter of more than 12 mm during the first year of life
Tears in the Descemet membrane (Haab striae)
Unilateral or bilateral myopic shift
Optic nerve cupping greater than 0.3
Any cup asymmetry associated with intraocular pressure (IOP) above the high teens
Optic nerve damage - Resulting in myopia, anisometropia, amblyopia, strabismus, and visual field defects
In young patients, examination under anesthesia or deep sedation is necessary to confirm the diagnosis of glaucoma. Careful assessment in each eye of IOP, corneal diameter, cycloplegic refraction, axial length, and optic nerve cupping, as well as gonioscopic examination, is mandatory.
Cerebrospinal fluid (CSF) protein may be elevated, presumably secondary to microhemorrhage. Note that a major intracranial hemorrhage itself is rare in SWS, although microhemorrhage may be common.
Computed tomography (CT) scanning
Magnetic resonance imaging (MRI)
MRI with gadolinium
Functional imaging - With single-photon emission computed tomography (SPECT) or positron emission tomography (PET) scanning
In the diagnosis of diffuse choroidal hemangioma, A-scan and B-scan ultrasonography may be useful diagnostic aids. B-scan ultrasonography characteristically shows a solid, echogenic mass, whereas A-scan ultrasonography demonstrates high internal reflectivity.
Electroencephalography (EEG) is used for the evaluation of seizures; it can also localize seizure activity when epilepsy surgery is considered for refractory seizures.
Medical care in SWS includes anticonvulsants for seizure control, symptomatic and prophylactic therapy for headache, glaucoma treatment to reduce IOP, and laser therapy for the PWS.
An anticonvulsant with efficacy in focal seizures is preferable in SWS. The chance of achieving seizure control with medical therapy in patients with SWS varies.
The goal of treatment is control of IOP to prevent optic nerve injury. This can be achieved with the following agents:
Beta-antagonist eye drops - Decrease the production of aqueous fluid
Carbonic anhydrase inhibitors - Also decrease production of aqueous fluid
Adrenergic eye drops and miotic eye drops - Promote drainage of aqueous fluid
Dye laser photocoagulation
Treatment of the cutaneous PWS with dye laser photocoagulation has been helpful in reducing the cosmetic blemish from the cutaneous vascular dilatation. 
Surgery is desirable in patients with SWS who have refractory seizures, glaucoma, or specific problems related to various SWS-associated disorders, such as scoliosis. 
Surgical procedures for seizures that are refractive to medical treatment include the following  :
Focal cortical resection
Vagal nerve stimulation (VNS)
Procedures for the treatment of diffuse choroidal hemangiomas with retinal detachment include the following:
Cryotherapy and diathermy
Xenon arc or argon laser photocoagulation
Subretinal fluid drainage
A retrospective analysis of five patients treated for DCH associated with Sturge-Weber syndrome found that ruthenium-106 plaque radiotherapy is an effective and safe treatment. 
Surgical options for glaucoma in SWS include the following:
Full-thickness filtration surgery
Partial-thickness filtration surgery (trabeculectomy)
Argon laser trabeculoplasty
Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser goniotomy
Sturge-Weber syndrome (SWS), also called encephalotrigeminal angiomatosis, is a neurocutaneous disorder with angiomas that involve the leptomeninges (leptomeningeal angiomas [LAs]) and the skin of the face, typically in the ophthalmic (V1) and maxillary (V2) distributions of the trigeminal nerve. Extracranial angiomas and soft-tissue overgrowth also may occur in SWS. (See Pathophysiology, Etiology, and Clinical Presentation.)
The hallmark of SWS is a facial cutaneous venous dilation, also referred to as a nevus flammeus or port-wine stain (PWS), which is present in as many as 96% of patients and is visible at birth (see the image below). The facial venous dilation appears as 1 or several dull red patches of irregular outline that are situated along, but are not limited to, the distribution of 1 or more divisions of the trigeminal nerve. [7, 8, 9] SWS belongs to a group of disorders collectively known as the phakomatoses ("mother-spot" diseases). (See Pathophysiology and Clinical Presentation.)
Laser therapy is available for the PWS. Although concerns have been raised that laser therapy to treat PWS might cause or worsen glaucoma or ocular hypertension; a 2009 retrospective review did not reveal evidence to support this. (See Treatment.) 
In the brain, LAs demonstrated by structural neuroimaging may be unilateral or bilateral  ; unilateral angiomas are more common. Functional neuroimaging may demonstrate a greater area of involvement than structural neuroimaging.  This is called a structural-versus-functional mismatch. (See Workup.)
The neurologic manifestations of SWS vary, depending on the location of the LAs (which most commonly are located in the parietal and occipital regions) and the secondary effects of the angiomas. These neurologic morbidities include the following:
Seizures - May be intractable
Focal deficits - Including hemiparesis and hemianopsia, both of which may be transient (called "strokelike episodes")
Developmental disorders - Including developmental delay, learning disorders, and mental retardation/intellectual disability; more common when angiomas are bilateral
Focal or generalized motor seizures usually begin in the first year of life. Profound seizure activity sometimes may be observed, with resultant further neurologic and developmental deterioration.  Seizure control is thought to improve the neurologic outcome, and epilepsy surgery may be beneficial for refractory seizures. Therefore, diagnosing and treating the disease early, before permanent damage to the brain occurs, is preferable. (See Prognosis and Treatment.)
Progressive, characteristic calcifications in the external layers of the cerebral cortex underlying the angiomatosis associated with ipsilateral cortical atrophy frequently develop and progress with age, occasionally extending anteriorly to the frontal and temporal lobes. (See Pathophysiology and Etiology.)
Certain CNS malformations have been associated with SWS; other neurocutaneous disorders are included in the differential diagnosis.
The primary complications involving the ipsilateral eye are buphthalmos and glaucoma, with treatment aimed at controlling the intraocular pressure (IOP) and preventing progressive visual loss and blindness.
SWS is referred to as complete when both CNS and facial angiomas are present, and incomplete when only the face or CNS is affected. The Roach Scale is used for classification, as follows  :
Type I - Facial and leptomeningeal angiomas; patient may have glaucoma
Type II - Facial angioma alone (no CNS involvement); patient may have glaucoma
Type III - Isolated LA; usually no glaucoma
Examples of ocular manifestations of SWS are shown in the images below.
SWS is caused by residual embryonal blood vessels and their secondary effects on surrounding brain tissue. A vascular plexus develops around the cephalic portion of the neural tube, under ectoderm destined to become facial skin. Normally, this vascular plexus forms in the sixth week and regresses around the ninth week of gestation. Failure of this normal regression results in residual vascular tissue, which forms the angiomata of the leptomeninges, face, and ipsilateral eye. 
From a review of pathologic specimens, Norman and Schoene thought that blood flow abnormalities in the LA caused increased capillary permeability, stasis, and anoxia.  Garcia et al and Gomez and Bebin reported that venous occlusion may actually cause the initial neurologic event, either a seizure, transient hemiparesis, or both, thereby beginning the process. [19, 20]
A "vascular steal phenomenon" may develop around the angioma, resulting in cortical ischemia. Recurrent seizures, status epilepticus, intractable seizures, and recurrent vascular events may aggravate this steal further, with an increase in cortical ischemia, resulting in progressive calcification, gliosis, and atrophy, which in turn increase the chance of seizures and neurologic deterioration. [21, 22]
Disease progression and neurologic deterioration may occur in SWS. Although the actual LA is typically a static anatomic lesion, Maria et al, Reid et al, and Sujansky and Conradi have clearly documented the progressive nature of SWS. [23, 24, 25]
Udani et al followed the natural disease course and magnetic resonance imaging (MRI) findings of 9 patients with SWS. They found that earlier onset seizures correlated with more residual neurologic deficits and worse focal cerebral atrophy and that in most cases the course stabilized after age 5 years. 
Seizure control, aspirin therapy, and early surgical treatment may prevent neurological deterioration. 
The main ocular manifestations (ie, buphthalmos, glaucoma) occur secondary to increased IOP with mechanical obstruction of the angle of the eye, elevated episcleral venous pressure, or increased secretion of aqueous fluid.
The etiology of SWS is unclear, although Huq et al reported evidence of somatic mosaicism in 4 patients with SWS. [27, 28] Two had skin biopsy from port-wine stains, and the other 2 had LAs from hemispherectomy. Inversion of chromosome arm 4q and trisomy 10 were seen in one patient each.
Malformed cortical vessels in SWS have been reported to be innervated only by noradrenergic sympathetic nerve fibers,  and increased endothelin-1 expression has also been seen in malformed intracranial vessels. These findings may suggest increased vasoconstriction in these abnormal blood vessels, as endothelin-1 is a peptide associated with vasoconstriction.
Fibronectin is a molecule important in regulating angiogenesis, maintenance of the blood-brain barrier, and blood vessel structure and function, as well as brain tissue responses to seizures. Comi et al reported that, in patients with SWS, decreased expression of fibronectin was noted in the leptomeningeal blood vessels, while increased expression was noted in the parenchymal vessels. The leptomeningeal blood vessel circumference was decreased, while blood vessel density was increased in SWS. 
Overall, in SWS, a somatic mutation appears to cause alterations in regulation of the structure and function of blood vessels, innervation of the blood vessels, and expression of extracellular matrix and vasoactive molecules.
Glaucoma in SWS is produced by mechanical obstruction of the angle of the eye, elevated episcleral venous pressure, or hypersecretion of fluid by either the choroidal hemangioma or ciliary body. The anterior chamber angle abnormality is consistently seen in the infantile glaucoma cases in SWS, while increased episcleral venous pressure may have a key role in late-onset glaucoma cases in SWS. Decreased vision and blindness result from untreated glaucoma, with increased IOP leading to optic nerve damage. An acceptable range of IOP is 10-22 mm Hg. Enlargement of the eye occurs from the same mechanisms as glaucoma.
Occurrence in the United States
According to Nelson's Textbook of Pediatrics, the incidence of SWS is estimated at 1 person per 50,000.  The inheritance is sporadic, and no regional differences in incidence have been identified. The incidences of the major clinical manifestations of SWS are listed in Table 1.
Table 1. Clinical Manifestations of Sturge-Weber Syndrome (Open Table in a new window)
|Clinical Manifestation||Incidence Rate|
|Risk of SWS with facial PWS||8%|
|SWS without facial nevus||13%|
|Bilateral cerebral involvement||15%|
|Developmental delay and mental retardation||50-75%|
Sturge-Weber syndrome is found worldwide. Generally, the condition is easily diagnosed at birth or in early infancy based on the external clinical signs alone. However, the development of morbidity from secondary changes and complications occurs throughout life.
The typical patient presents at birth with facial angiomas; however, not all children with facial angiomas and PWS have SWS, which raises certain diagnostic and prognostic concerns. 
In incomplete SWS (type III, Roach Scale), CNS angiomas occur without cutaneous features; therefore, no suspicion of SWS arises until a seizure or other neurologic problem develops. Thus, the diagnosis of SWS is not always straightforward.
Secondary glaucoma may present at any age, although early onset is the rule, with approximately 60% of glaucomas presenting at birth or in early infancy and another 30% presenting during childhood. The median ages reported for onset of visual symptoms related to secondary retinal changes range from age 8-20 years.
Neurologic and developmental morbidities in Sturge-Weber syndrome (SWS) include the following:
The development of seizures and their age of onset may correlate with the degree of neurologic involvement. Neurologic dysfunction increases with bilateral PWS. Patients may experience complications related to refractory seizures and anticonvulsants, they may suffer visual loss and blindness from glaucoma, and they may display cosmetic deformities and other manifestations of soft-tissue involvement.
The glaucoma associated with SWS is a significant cause of morbidity because of its early onset and resistance to conventional forms of treatment. Glaucoma has been estimated to occur in 30-71% of patients with Sturge-Weber syndrome.
Factors predicting a poor outcome (or indicating the need for surgery) in SWS include the following:
Early seizure onset
Extensive leptomeningeal angioma (LA)
Medically refractive seizures
Relapsing or permanent motor deficits
Headaches or mild trauma associated with transient motor deficits
Evidence of progressive neurologic damage
Focal seizures with subsequent generalization
Increasing seizure frequency and duration
Increasing duration of postictal deficits
Increasing focal or diffuse atrophy
Progressive atrophy or calcifications
Development of hemiparesis
Deterioration in cognitive functioning (loss of intellectual abilities)
Facial nevi are congenital macular lesions that can be progressive; they may be a light pink color initially and then progress to a dark red or purple nodular lesion. These may be isolated to the skin, associated with lesions in the choroidal vessels of the eye or the leptomeningeal vessels of the brain, or even located on other body areas.  A facial nevus, or PWS may be difficult to visualize in a patient with dark skin pigmentation.
Not all people with a PWS have SWS; the overall incidence of SWS has been reported to be 8-33% in individuals with a PWS. Several studies have evaluated this specifically.
A study by Enjolras et al indicated that in patients with a PWS, SWS occurs only when the nevus involves the V1 (ophthalmic) distribution of the trigeminal nerve. In their retrospective review, the investigators studied data from 106 patients with a facial PWS, 12 of whom had SWS and 4 of whom had glaucoma without pial lesions. No patients who had involvement of the V2 (maxillary) and/or V3 (mandibular) area without V1 involvement had SWS. 
Patients in the study who were considered to be at high risk for SWS were those with involvement of the entire V1 area; 11 of 25 patients with full V1 involvement had SWS. Patients with only partial involvement of V1 were at low risk (only 1 of 17 patients had SWS).
In a study of 121 patients with facial nevi affecting the skin in the distribution of the trigeminal nerve, Bioxeda et al concluded that only those persons with V1 involvement were at risk for epilepsy or glaucoma. The investigators found that glaucoma and epilepsy were present in 23 (17%) and 17 (14%) patients, respectively, with V1 involvement occurring in all 40 of these individuals. 
The investigators also found that the facial nevi were located predominantly over the distribution of the V2 branch of the trigeminal nerve in 88% of these individuals, either isolated to the V2 branch or also involving the V1 and/or V3 branches. An extrafacial PWS was more common when V3 was involved. The lesions were unilateral in 86% of patients, and bilateral in 14% of them.
In a similar, but larger, study, Tallman et al found that only patients with a PWS involving the distributions of the V1 and V2 branches of the trigeminal nerve had CNS or eye involvement. The investigators reported on 310 patients with facial nevi, 85% of who had unilateral involvement, 15% of whom had bilateral involvement, and 68% of who had involvement of more than 1 dermatome. Overall, in patients with trigeminal involvement, only 8% had CNS and eye involvement; 24% of those with bilateral lesions had eye or CNS involvement, compared with only 6% of patients with unilateral lesions. 
Tallman and colleagues also found that all patients with eye or CNS involvement had lesions on the eyelids; 91% of these had both upper and lower eyelid involvement, whereas 9% had only lower eyelid involvement. No patients with upper eyelid involvement alone had eye or CNS involvement. Three of 16 patients with involvement of V1, V2, and V3 had eye and/or CNS involvement. The authors recommended screening for glaucoma and CNS involvement when the PWS involved the eyelids, with unilateral V1, V2, and V3 lesions, or with bilateral lesions.
Patients identified by the Sturge-Weber Foundation had a different pattern of involvement—170 of 171 patients had a craniofacial PWS, with unilateral involvement in 83 patients (49%) and bilateral involvement in 86 patients (51%).
Note that an extrafacial PWS may have associated intracranial abnormalities; for example, in Klippel-Trenaunay-Weber syndrome, neuroimaging may show findings similar to those of SWS,  and a cervical PWS has been associated with occipital calcifications. 
The incidence of epilepsy in patients with SWS is 75-90%. Seizures result from cortical irritability caused by cerebral angioma, through mechanisms of hypoxia, ischemia, and gliosis. Dual pathology, such as microgyria, also may be present, which also contributes to epileptogenesis. Seizures may be intractable in some patients.
Garcia et al reported that a child with SWS could have an early normal neurologic course, with a seizure as the presenting manifestation of a neurologic problem. 
In a survey of cases identified by the Sturge-Weber Foundation,  seizures occurred in 136 of 171 patients, with the age of onset ranging from birth to 23 years and the median age of onset being 6 months. About 75% of the patients had onset during the first year of life; 86%, before age 2 years; and 95%, before age 5 years. Seizures occurred in 71% of those with unilateral and 87% of those with bilateral disease.
Bebin and Gomez, from the Mayo Clinic, reported that seizures occurred in 80% of patients with SWS (72% with unilateral involvement vs 93% with bilateral involvement), with the median age of onset being 8.5 months in patients with unilateral PWS and 4 months in patients with bilateral PWS. 
Oakes reported seizures in 24 (80%) of 30 patients with SWS, with a mean age of onset of 6 months. 
Bebin and Gomez reported an earlier onset of seizures in patients with bilateral involvement (mean ages of seizure onset were 6 months with bilateral disease and 24 months with unilateral disease).  Pascual-Castroviejo et al showed that patients with more frequent seizures tended to have an earlier seizure onset (mean seizure onset at age 5-6 months compared with a mean onset at age 2 years in those with less severe involvement). 
Pascual-Castroviejo et al reported seizures in 32 (80%) of 40 patients. Seizures began during a febrile illness in 10 patients (31%; fever could be a precipitant at any age), while infantile spasms occurred in 2 patients (6%). 
In the patients reported by the Sturge-Weber Foundation, 50% had complete control and 39% had partial control of seizures with medications. Those with a later age of seizure onset had a lower incidence of developmental delay and fewer special educational needs.
According to Roach, the onset of seizures prior to age 2 suggests a greater chance of refractory epilepsy and mental retardation.  Patients with refractory seizures are more likely to have mental retardation, since those individuals have more extensive brain involvement.
In a report by Sujansky and Conradi, using data obtained through the Sturge-Weber Foundation,  overall developmental delay occurred in 97 (58%) of 168 patients with SWS. Early developmental delay, however, occurred in 71% of patients with seizures and in only 6% of those without seizures. Patients with a later seizure onset also had a lower incidence of developmental delay and fewer special education needs.
However, even with seizure onset within the first year, Erba and Cavazzuti reported satisfactory control in 50% of patients, with 30% of patients being seizure free for at least 2 years. Among the other patients, 17% had an average of 1 seizure per month, and 33% were considered to have poorly controlled seizures, defined as greater than 1 seizure per week.  Therefore, early seizures may not predict either the severity of subsequent epilepsy or severe mental retardation.
Maria et al divided their patients into 2 groups by age for a longitudinal study—those aged 1-3 years versus those aged 10-22 years—and found no difference in clinical outcomes with early onset seizures. 
Focal versus generalized seizures
Since the lesion responsible for epilepsy in SWS is focal, the majority of seizures are focal seizures. In a study of 76 patients, Bebin and Gomez reported partial seizures in 35 patients (46%), generalized seizures in 15 of them (20%), and both in 26 of them (34%). 
Pascual-Castroviejo et al reported seizures in 32 (80%) of 40 patients with SWS; 22 (69%) of them had focal seizures contralateral to the PWS, with subsequent generalization in 6 patients; 8 patients (25%) had generalized seizures at onset, and infantile spasms occurred in 2 patients (6%). 
Prolonged seizures cause neurologic injury secondary to metabolic disturbances such as hypoxemia, hypoglycemia, hypotension, ischemia, and hyperthermia.
In an already compromised vascular system, such as a vascular steal from the angioma, seizures are more likely to cause injury, even when short. Episodes of status epilepticus are, therefore, especially dangerous in SWS. 
Transient episodes are referred to as strokelike episodes. These occurred in 14 (70%) of 20 patients described by Maria et al.  Garcia et al reported recurrent thrombotic episodes.  Stroke also may occur. The incidence of neurologic deficit is higher in adults; Sujansky and Conradi reported an occurrence in 34 (65%) of 52 patients,  results that demonstrated the progressive nature of SWS.
The incidence of hemiparesis is approximately 33% in patients with SWS, varying from 25-56%. The disorder occurs secondary to ischemia with venous occlusion and thrombosis. Commonly, transient weakness may occur with seizures and may increase with recurrent seizures. Transient hemiplegia may be accompanied by migraine headache, suggesting a vascular mechanism. However, Jung et al reported a case of a woman with headache and left hemiparesis but no neuroimaging evidence of acute thrombosis formation or recent vascular event. 
The mechanism for hemianopsia is similar to that for hemiparesis and is dependent on the location of the lesions. Uram and Zullabigo reported hemianopsia in 11 (44%) of 25 patients.  In 2009, Shimakawa et al reported a rare case of recurrent homonymous hemianopsia that became permanent. 
Developmental delay and mental retardation
Related to the degree of neurologic involvement, developmental delay and mental retardation occur in 50-60% of patients with SWS; they are more likely to exist in patients with bilateral involvement.  Bebin and Gomez reported normal mental functioning in only 8% of patients with bilateral SWS. 
In a detailed study of 10 patients with SWS, Maria et al found developmental delay and learning problems in all 10 and attention deficit hyperactivity disorder in 3.  Using a combination of computed tomography (CT) scanning, MRI, and functional imaging with single-photon emission CT (SPECT) scanning, abnormalities were found bilaterally the majority of patients, including extensive abnormalities in glucose metabolism and cerebral perfusion. These results may account for the high incidence of developmental delay, mental retardation, and learning problems seen in SWS.
Seizures are also associated with a higher incidence of mental retardation, and regression may be related to the frequency and severity of seizures as well.
Alkonyi et al reported on 14 patients with bilateral SWS who had an asymmetrical pattern on positron-emission tomography (PET) scanning and found that bilateral frontal and temporal hypometabolism was associated with poor developmental outcome. Good seizure control and only mild to moderate developmental impairment was seen in about 50% of the patients with bilateral SWS. 
Occurring secondary to vascular disease, these have the symptoms of a migraine headache and are considered "symptomatic migraines."
In the aforementioned study by the Sturge-Weber Foundation, headaches occurred in 132 (77%) of 171 of patients of all ages and in 28 (62%) of 45 adults. In reports by Maria et al, headaches occurred in 60% of patients. [23, 46, 2]
In a specific study of headaches in SWS reported by Klapper, 71 patients identified by the Sturge-Weber Foundation responded to a questionnaire about headaches.  Migraine headache occurred in 28% of patients, and neurologic deficits occurred in 58% of these patients during the migraine. The prevalence of migraine was 31% in children younger than 10 years, much greater than the 5% prevalence in the general population.
Treatment includes yearly examinations to look for optic nerve damage (with measurement of IOP and visual fields) and for corneal diameter and refractive changes in children.
Glaucoma usually occurs only with an ipsilateral facial PWS, although the glaucoma may be bilateral when facial involvement is bilateral. Contralateral glaucoma may develop, although rarely. Glaucoma also may occur without neurologic involvement (Type II, Roach Scale).
Sullivan et al reviewed ocular abnormalities in 51 patients with SWS.  Of these, 36 patients (71%) had glaucoma, with onset before age 24 months in 26 (51%) patients; 35 (69%) patients had conjunctival or episcleral hemangiomas; and 28 (55%) patients had choroidal hemangiomas.
With time, choroidal hemangioma may cause other secondary changes, including the following:
Retinal pigment epithelium degeneration
Cystic retinal degeneration
Retinal vascular tortuosity, iris heterochromia, optic disc coloboma, and cataracts have also been seen in patients with SWS.
The Sturge-Weber Foundation data show that 82 (48%) of 171 patients had glaucoma. Of these patients, 61% developed glaucoma during the first year of life; a second peak occurred in children aged 5-9 years, when it developed in another 11 (15%) patients.
An increased rate of growth hormone deficiency was found in SWS, as identified from a registry of 1653 patients.  Comi et al found central hypothyroidism in 2 children out of 83 (2.4%) with SWS and brain involvement, indicating that central hypothyroidism is much more prevalent in such patients than it is in the general population. 
The Sturge-Weber Foundation survey indicated that other abnormalities occurred in all 171 patients in the study. These included other cutaneous lesions in all patients and body asymmetry in 164 (96%) of 171 patients, with soft-tissue hypertrophy occurring in 38 (23%) of the 164 patients and scoliosis existing in 11 (6.7%) of the 164 patients. Basal cell carcinoma has been reported to occur within a PWS. 
Adults with SWS
Few data are available on adults with SWS. Sujansky and Conradi studied the outcomes in 52 adults older than 18 years who had SWS and were identified by the Sturge-Weber Foundation.  The age of onset of glaucoma ranged from 0-41 years, with a median of 5 years.
Seizures occurred in 83% of the patients, glaucoma in 60%, and a neurologic deficit—such as stroke, paralysis, spasticity, or weakness—in 65%. The age of onset of seizures ranged from 0-23 years, with a median of 6 months.
Seizure outcome was known in 41 patients in the study, with full control attained in 11 (27%) patients, a decrease in seizures achieved in (49%) 20 patients, and no improvement found in 10 (24%) patients. The morbid conditions associated with these seizures are listed in Table 2, below.
Headache occurred in 28 (62%) of 45 patients, with age of onset ranging from early childhood to age 38 years and with a median age of onset of 18 years. The headache frequency could be determined in 23 patients: daily in 9 patients (39%), 1-4 times per week in 4 (17%), 1-2 times per month in 6 (26%) patients, and rare in 4 patients (17%).
Headaches were associated with increased discoloration of facial PWS, auras, nausea/vomiting, dysarthria, dizziness, and feelings of facial pulsation.
Table 2. Developmental Morbidity Associated with Seizures in Adults with SWS (Open Table in a new window)
|With Seizures (%)||Without Seizures (%)|
|Need for special education||71||0|
What would you like to print?
- Approach Considerations
- Pharmacologic Treatment of Seizures
- Pharmacologic Treatment of Glaucoma
- Strokelike Events
- Port-Wine Stain
- Surgical Treatment of Seizures
- Surgical Treatment of Diffuse Choroidal Hemangiomas
- Glaucoma Surgery
- Correction of Anisometropia and Strabismus
- Long-Term Monitoring
- Show All